TriMethyl-Histone H3 (Lys27)抗体;TriMethyl-Histone H3 (Lys27) Antibody—艾普蒂

+ +

•  

   

     Western blot analysis of Histone H3 (tri methylLys27) in C6, Jurkat lysates using TriMethyl-Histone H3 (Lys27) antibody.    

  
  

•  

   

     Immunocytochemistry analysis of TriMethyl-Histone H3 (Lys27) (green) in Hela using TriMethyl-Histone H3 (Lys27) antibody,and DAPI(blue)    

  
  

•  

   

     Immunohistochemistry analysis of paraffin-embedded Human lung cancer using TriMethyl-Histone H3 (Lys27) antibody.High-pressure and temperature Sodium Citrate pH 6.0 was used for antigen retrieval.    

  
  

TriMethyl-Histone H3 (Lys27) [H3K27me3] antibodies are essential tools for studying post-translational modifications associated with epigenetic regulation. Histone H3 lysine 27 trimethylation is a conserved marker of transcriptionally repressive chromatin, primarily catalyzed by Polycomb repressive complex 2 (PRC2), with EZH2 or EZH1 as the catalytic subunit. This modification plays a critical role in gene silencing, X-chromosome inactivation, and maintenance of stem cell pluripotency. Aberrant H3K27me3 levels are linked to developmental disorders and cancers, such as gliomas, where H3K27M mutations drive oncogenesis, and certain solid tumors with PRC2 dysregulation.

H3K27me3-specific antibodies are widely used in chromatin immunoprecipitation (ChIP), immunofluorescence (IF), and Western blotting to map repressive domains, assess PRC2 activity, or investigate crosstalk with activating marks like H3K4me3. They are critical for studying cellular differentiation, tumor progression, and epigenetic therapies targeting PRC2 (e.g., EZH2 inhibitors). Validation in knockout models or enzymatic demethylation controls is recommended due to potential cross-reactivity with other methylated residues. These antibodies also aid in diagnosing H3K27-altered cancers, highlighting their dual research and clinical utility.